Tumour‐associated autoantibodies may be promising biomarkers that could facilitate breast
cancer (BC) diagnosis and improve patient outcomes. This review aims to identify the …

Background The increasing incidence of breast cancer necessitates the need to explore
alternate screening strategies that circumvent the setbacks of conventional techniques …

Tumor‐associated autoantibodies (TAAb) could be serological tumor markers. This study
aims to discover novel TAAb signatures for breast cancer (BC) detection. The protein …

The widespread use of screening mammography has resulted in increased detection of
early‐stage breast disease, particularly for in situ carcinoma and early‐stage breast cancer …

Background: There is increasing evidence that the immune system produces a humoral
response to cancer-derived antigens. This study assessed the diagnostic potential of …

549 Background: Immune responses to a number of tumour-associated antigens have been
reported, although their suitability, individually, as diagnostic indicators has not been …

Breast cancer is the most common cancer among women and accounts for 6% of all cancer
deaths. Current screening modalities for breast cancer diagnosis include mammography …

Introduction Only a limited number of tumor markers for breast cancer are currently
available. Antibodies to tumor-associated proteins may expand the number of available …

In addition to their historical role, autoantibodies appear promising as biomarkers to facilitate
diagnosis, improve patient outcome and decrease mortality in cancer. Autoantibodies may …

Breast cancer is the most common cancer in women worldwide and is a substantial public
health problem. Screening for breast cancer mainly relies on mammography, which leads to …